Keto-Diet, A Better Nutritional Approach for MS Patients
Obesity is a recognized risk factor for multiple sclerosis (MS) and, dietary intake is one potentially modifiable environmental contributor to MS has garnered much interest from people living with MS. A recent study suggests that the ketogenic diet (KD) is safe and beneficial in reducing a few symptoms for people with MS when used for over 6 months.
The study findings were published in the Journal of Neurology, Neurosurgery & Psychiatry on 13 April 2022.
KDs are high-fat, low-carbohydrate diets that mimic a fasting state. KDs, in particular, may alter key aspects of MS pathogenesis via ketosis-induced upregulation of antioxidant pathways, reduced effector cell immunity, and enhanced CNS bioenergetics, which may provide an alternative energy source to vulnerable neurons. To further explore, Dr J Nicholas Brenton and his team conducted a study to assess the tolerability of a ketogenic diet in patients with relapsing multiple sclerosis and define the impact on laboratory and clinical outcome metrics.
In this prospective, intention-to-treat KD intervention, the researchers included sixty-five patients with relapsing MS and followed them for 6-months. They monitored adherence with daily urine ketone testing. At baseline, fatigue, depression and quality of life (QoL) scores were obtained in addition to fasting adipokines and MS-related clinical outcome metrics. They further repeated the baseline metrics at 3 and/or 6 months on diet.
Key findings of the study:
- Upon analysis, the researchers found that the patients exhibited significant reductions in fat mass and showed a nearly 50% decline in self-reported fatigue and depression scores.
- They also found that MS QoL physical health (67±16 vs 79±12) and mental health (71±17 vs 82±11) composite scores increased on diet.
- They noted significant improvements in Expanded Disability Status Scale scores (2.3±0.9 vs 1.9±1.1), 6-minute walk (1631±302 vs 1733±330 ft) and Nine-Hole Peg Test (21.5±3.6 vs 20.3±3.7 s).
- They further noted that serum leptin was lower (25.5±15.7 vs 14.0±11.7 ng/mL) and adiponectin was higher (11.4±7.8 vs 13.5±8.4 µg/mL) on the KD.
The authors concluded, "KDs are safe and tolerable over a 6-month study period and yield improvements in body composition, fatigue, depression, QoL, neurological disability and adipose-related inflammation in persons living with relapsing MS".
For further information:
DOI: http://dx.doi.org/10.1136/jnnp-2022-329074
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.